LINCOLN PHARMA LTD
LINCOLN · General/Diversified · NSE
₹638
Current Market Price
Fair Value (DCF)
₹992
Discount to FV
+55.6%
Updated just now
YieldIQ Score
40/100
Piotroski F-Score
8/9
Economic Moat
Wide
Confidence
56%
ROE
12.3%
Debt/Equity
0.00
WACC
11.1%
Market Cap
₹1,277 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
18.3%
Return on capital employed
EV / EBITDA
12.2×
Enterprise multiple
Debt / EBITDA
0.0×
Leverage vs earnings
Interest Coverage
111.1×
EBIT covers interest
Current Ratio
4.71×
Short-term liquidity
Asset Turnover
0.80×
Revenue per ₹ of assets
Revenue CAGR (3Y)
9.9%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹637.8
Bear case
Discount -18.1%
Base case
Discount +35.7%
Bull case
Discount +46.4%
Ratio Trends
LINCOLN · last 8 annual periods
ROE
12.3%
ROCE
18.3%
Operating Margin
—
Debt / Equity
0.00×
PE
9.3×
EV / EBITDA
6.1×
Historical Financials
LINCOLN · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 NSE_XBRL | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹413 Cr | ₹468 Cr | ₹505 Cr | ₹571 Cr | ₹615 Cr | +10.5% |
| EBITDA | — | ₹105 Cr | ₹111 Cr | ₹134 Cr | ₹123 Cr | +4.1% |
| EBIT | ₹82.5 Cr | ₹97.4 Cr | ₹103 Cr | ₹124 Cr | — | +10.7% |
| PAT | ₹60.4 Cr | ₹69.4 Cr | ₹72.9 Cr | ₹93.3 Cr | ₹82.3 Cr | +8.1% |
| EPS (diluted) | ₹30.20 | ₹34.63 | ₹36.40 | ₹46.58 | — | +11.4% |
| CFO | ₹71.4 Cr | ₹76.1 Cr | ₹39.3 Cr | ₹63.2 Cr | ₹93.0 Cr | +6.8% |
| CapEx | — | ₹-45.5 Cr | ₹-14.3 Cr | ₹-39.6 Cr | ₹-19.2 Cr | — |
| FCF | — | ₹30.6 Cr | ₹25.0 Cr | ₹23.6 Cr | ₹73.8 Cr | +24.6% |
| Total Assets | — | ₹534 Cr | ₹587 Cr | ₹700 Cr | ₹797 Cr | +10.5% |
| Total Debt | — | ₹2.0 Cr | ₹2.0 Cr | ₹1.1 Cr | — | -15.0% |
| Shareholders' Equity | — | ₹433 Cr | ₹502 Cr | ₹593 Cr | ₹672 Cr | +11.6% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
LINCOLN vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 BAJAJHCARE BAJAJHCARE | — | — | Pending | 3.0% | — |
INDSWFTLAB INDSWFTLAB | — | — | Pending | 21.4% | — |
JAGSNPHARM JAGSNPHARM | — | — | Pending | 15.6% | 28.7× |
 SAKAR SAKAR | — | — | Pending | 6.1% | — |
SYNCOMF SYNCOMF | — | — | Pending | 14.4% | — |
Click a ticker to view its fair-value analysis.
Dividend History
10 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹8.10/sh
Last payout
2025-09-12
₹1.80
Peak payout
₹1.80
Trailing yield
0.28%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
AI Analysis Summary
Model-generated description of metrics. Not investment advice. LINCOLN PHARMA LTD (LINCOLN.NS) trades at 637.80 vs a model fair value of 992.28, a gap of 55.6%. Piotroski F-score: 8/9. Moat label: Wid...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of LINCOLN →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for LINCOLN →
Compare
Head-to-head with peers
Compare LINCOLN side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse LINCOLNNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.